Home | Business News | Browse by Publication | B | Biotech Business

DUSKA THERAPEUTICS PLANS NDA 505(B)(2) FILING FOR ATPACE.

Publication: Biotech Business
Publication Date: 01-JUN-08 		Format: Online
Delivery: Immediate Online Access

Article Excerpt
Duska Therapeutics, Inc. (BULLETIN BOARD: DSKA), La Jolla, Calif., a biotechnology company developing medical products based on adenosine 5'-triphosphate (ATP) and P2 receptor- related technologies, has announced that the company's management and clinical and regulatory consultants met on April 16 with members of the United States Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. The purpose of the meeting was to discuss the appropriate regulatory pathway for filing a marketing application of...

Access Full Article, Compliments of Goliath

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Biotech Business
METABASIS GETS GOOD RESULTS FROM MB07803 PHASE 2A TRIAL., June 01, 2008

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.